UTAH MEDICAL PRODUCTS INC
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
UTMD$72.87+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Balance Sheets
| UTAH MEDICAL PRODUCTS, INC. | ||||||
|---|---|---|---|---|---|---|
| CONSOLIDATED BALANCE SHEETS | ||||||
| December 31, 2024 and 2023 | ||||||
| (In thousands) | ||||||
| 2024 · 2023 | ||||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash | $82,976 | $92,868 | ||||
| Accounts and other receivables, net (note 2) | 4,094 | 3,391 | ||||
| Inventories (note 2) | 8,812 | 9,582 | ||||
| Prepaid expenses and other current assets | 448 | 428 | ||||
| Total current assets | 96,330 | 106,269 | ||||
| Property and equipment, net (notes 4 and 10) | 9,763 | 10,551 | ||||
| Goodwill | 13,580 | 13,692 | ||||
| Other intangible assets (note 2) | 53,772 | 54,296 | ||||
| Other intangible assets - accumulated amortization | (50,907) | (49,350) | ||||
| Other intangible assets - net (note 2) | 2,865 | 4,946 | ||||
| Total assets | $122,538 | $135,458 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | $696 | $769 | ||||
| Accrued expenses (note 2) | 3,061 | 3,941 | ||||
| Total current liabilities | 3,757 | 4,710 | ||||
| Long term lease liability | 282 | 295 | ||||
| Long term income tax payable (REPAT tax) (note 7) | - | 698 | ||||
| Deferred tax liability - intangible assets | 603 | 1,120 | ||||
| Deferred income taxes (note 7) | 469 | 322 | ||||
| Total liabilities | 5,111 | 7,145 | ||||
| Commitments and contingencies (notes 6 and 12) | - | - | ||||
| Stockholders' equity: | ||||||
| Common stock, $0.01 par value; 50,000 shares authorized, issued 3,335 shares in 2024 and 3,630 shares in 2023 | 33 | 36 | ||||
| Accumulated other comprehensive loss | (11,908) | (10,658) | ||||
| Additional paid-in capital | - | 594 | ||||
| Retained earnings | 129,302 | 138,341 | ||||
| Total stockholders' equity | 117,427 | 128,313 | ||||
| Total liabilities and stockholders' equity | $122,538 | $135,458 | ||||
| See accompanying notes to financial statements. | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.